A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cilta-cel
DRUG: Talquetamab

Sponsor

Janssen Research & Development, LLC